In addition, polymorphisms associated with decreased IL-17 serum levels (IL23R G>A (rs11209026)) and decreased TNF-α serum levels (PTPN22 1858 G>A (rs2476601)) were associated with reduced risk of IBD. Here, PTPN22 is linked to inflammatory bowel disease.